Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer

BJU International

Volumn 98, Issue 1, 2006, Pages 20-27

  Mottet, Nicolas ^a   Prayer Galetti, Tommaso ^b   Hammerer, Peter ^c   Kattan, Michael W ^e   Tunn, Ulf ^d  

^a Clinique Mutualiste   (France)

^b UNIVERSITY OF PADOVA   (Italy)

^c Academic Hospital   (Germany)

^d Academic Hospital   (Germany)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Androgen ablation; Hormonal therapy; Intermittent androgen deprivation; Prostate cancer; PSA; Side effects; Tolerance

Indexed keywords

ANTIANDROGEN; ANTIDEPRESSANT AGENT; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; CLONIDINE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; ESTROGEN; FLUTAMIDE; GLUCOCORTICOID; GONADORELIN AGONIST; LEUPRORELIN; PHOSPHODIESTERASE V INHIBITOR; PHYTOESTROGEN; PROGESTERONE; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT ERYTHROPOIETIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SILDENAFIL; VENLAFAXINE; VERALIPRIDE; VITAMIN D;

ANDROGEN DEPRIVATION THERAPY; ANEMIA; BONE; BONE DEMINERALIZATION; BONE METASTASIS; BONE PAIN; BREAST DISEASE; CANCER HORMONE THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASTRATION; CLINICAL TRIAL; COGNITION; DEPRESSION; ERECTILE DYSFUNCTION; FATIGUE; FRACTURE; FRAGILITY FRACTURE; GYNECOMASTIA; HOT FLUSH; HUMAN; LIBIDO; LIBIDO DISORDER; LIFESTYLE; LIVER TOXICITY; MASTALGIA; METABOLIC DISORDER; NONHUMAN; OBESITY; OSTEOPOROSIS; POTENCY DISORDER; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; SELF ESTEEM; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SHORT SURVEY; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; ANEMIA; ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY; COGNITION DISORDERS; DEPRESSIVE DISORDER; FRACTURES, BONE; HUMANS; MALE; METABOLIC DISEASES; OSTEOPOROSIS; PAIN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RISK FACTORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TREATMENT OUTCOME;

EID: 33745172826     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06176.x     Document Type: Short Survey

References (88)

1. Cooperberg MR Broeing JM Litwin MS et al. CaPSURE Investigators. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CaPSURE), a national disease registry. J Urol 2004 171: 1393 401
2. Labrie F. Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer. J Androl 2004 25: 305 13
3. Klotz L. Hormone therapy for patients with prostate carcinoma. Cancer 2000 88 ( Suppl. 12 3009 14
4. Studer UE Whelan P Albrecht W et al. Patients with asymptomatic prostate cancer T.0-4 N.0-2 M.0 not suitable for local definitive treatment: do they need immediate androgen deprivation? Eur Urol 2005 4 ( Suppl. 3) 78: abstract 303
5. Cooperberg MR Grossfeld GD Lubeck DP Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003 95: 981 9
6. Walsh PC DeWeese TL Eisenberger MA. A structured debate: immediate versus deferred androgen suppression in prostate cancer - evidence for deferred treatment. J Urol 2001 156: 508 16
7. Labrie F Candas B Cusan L et al. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996 47: 212 7
8. Kirk D. Immediate versus deferred treatment for advanced disease. Cancer Surv 1995 23: 183 90
9. Huggins C Hodges CV. Studies on prostatic cancer. I. The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941 1: 293 7
10. Lunglmayr G Girsch E Meixner EM Viehberger G Bieglmayer C. Effects of long term GnRH analogue treatment on hormone levels and spermatogenesis in patients with carcinoma of the prostate. Urol Res 1988 16: 315 9
11. Peeling WB. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology 1989 33 ( Suppl. 5 45 52
12. Miyamoto H Messing EM Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004 61: 332 53
13. Smith MR. Complimentary and alternative therapies for advanced prostate cancer. Hematol Oncol Clin North Am 2001 15: 559 71
14. Oefelein MG Resnick MI. Effective testosterone suppression for patients with prostate cancer: is there a best castration? Urology 2003 62: 207 13
15. Potosky AL Legler J Albertsen PC et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the prostate cancer outcomes study. J Natl Cancer Inst 2000 92: 1582 92
16. Herr HW O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 2000 163: 1743 6
17. Almeida OP Waterreus A Spry N Flicker L Martins RN. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology 2004 29: 1071 81
18. Green JS. An investigation into the use of palliative care services by patients with prostate cancer. Am J Hosp Palliat Care 2002 19: 259 62
19. Bloomfield DJ Shilling V Edginton T Jenkins V. A longitudinal pilot study to investigate whether hormonal therapy for prostate cancer affects cognition. J Clin Oncol 2004 22 ( Suppl. 4646
20. Beer TM Bland LB Garzotto M Ryan CW Janowsky JS. Effect of high-dose estrogen on memory in men with prostate cancer. J Clin Oncol 2004 22 ( Suppl. 4650
21. Shanafelt TD Barton DL Adjei AA Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002 77: 1207 18
22. Spetz AC Zetterlund EL Varenhorst E Hammar M. Incidence and management of hot flashes in prostate cancer. J Support Oncol 2003 1: 263 6
23. de Voogt HJ Studer U Schroder FH Klijn JG de Pauw M Sylvester R. Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group. Eur Urol 1998 33: 152 8
24. Kruus LK Palmer S Malkowicz S Vaughn DJ Coyne JC. The influence of fatigue and hot flashes on the quality of life in prostate cancer patients. quality of life management. ASCO Annual Meeting 2001, May 12-15 San Francisco, USA. Abstract 1594
25. Steiner MS Raghow S. Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk. World J Urol 2003 21: 31 6
26. Eaton AC McGuire N. Cyproterone acetate in treatment of post-orchidectomy hot flushes. Double-blind cross-over trial. Lancet 1983 2: 1336 7
27. Quella SK Loprinzi CL Sloan J et al. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 1999 162: 98 102
28. Sloan JA Loprinzi CL Novotny PJ Barton DL Lavasseur BI Windschitl H. Methodologic lessons learned from hot flash studies. J Clin Oncol 2001 19: 4280 90
29. Aus G Abbou CC Bolla M et al. EAU guidelines on prostate cancer. Eur Urol 2005 48: 546 51
30. Sharifi N Gulley JL Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005 294: 238 44
31. Traish A Kim N. The physiological role of androgens in penile erection: regulation of corpus cavernosum structure and function. J Sex Med 2005 2: 759 70
32. Ross RW Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 2002 167: 1952 6
33. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997 157: 439 44
34. Dickman PW Adofsson J Astrom K Steineck G. Hip fractures in men with prostate cancer treated with orchiectomy. J Urol 2004 172: 2208 12
35. Smith MR Lee WC Krupsi T et al. Association between androgen deprivation therapy and fracture risk: a population-based cohort study in men with non-metastatic prostate cancer. J Clin Oncol 2004 22 ( Suppl. 4507
36. Shahinian VB Kuo YF Freeman JL Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005 352: 154 64
37. Cree M Soskolne CL Belseck E et al. Mortality and institutionalization following hip fracture. J Am Geriatr Soc 2000 48: 283 8
38. Center JR Nguyen TV Schneider D Sambrook PN Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999 353: 878 82
39. Conde FA Aronson WJ. Risk factors for male osteoporosis. Urol Oncol 2003 21: 380 3
40. Higano CS. Management of bone loss in men with prostate cancer. J Urol 2003 170: S59 64
41. Saad F Schulman CC. Role of bisphosphonates in prostate cancer. Eur Urol 2004 45: 26 34
42. Smith MR. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. Drugs Aging 2003 20: 175 83
43. Small EJ Smith MR Seaman JJ Petrone S Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003 21: 4277 84
44. Ockrim JL Lalani EN Banks LM et al. Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer. J Urol 2004 172: 2203 7
45. Saad F. Bone loss in prostate cancer: evaluation, treatment and prevention. Can J Urol 2005 12 ( Suppl. 1 71 6
46. Overman M Wang C Detrano R et al. Cardiovascular risk and sub-clinical atherosclerosis in prostate cancer: Patient with and without androgen ablation. J Clin Oncol 2004 22 ( Suppl. 4605
47. Yannucci J Manola J Garnick M Bubley G. The effect of androgen deprivation therapy (ADT) on lipid and HbA1c parameters. ASCO Annual Meeting 2005, May 13-17 Orlando, USA. Abstract 4562
48. Boccon-Gibod L Fournier G Bottet P et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol 1997 32: 391 6
49. Iversen P. Quality of life issues relating to endocrine treatment options. Eur Urol 1999 36 ( Suppl. 2 20 6
50. Boccardo F Barichello M Battaglia M et al. Italian Prostate Cancer Group. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. Eur Urol 2002 42: 481 90
51. Schroeder FH Whelan P de Reijke THM et al. members of the EORTC Genito-urinary Tract Cancer Cooperative Group. Metastatic prostate cancer - a randomized study of cyproterone acetate versus flutamide (EORTC 30892 - final analysis). Eur Urol 2000 37: 127, A505
52. Sieber PR Keiller DL Kahnoski RJ et al. Bone mineral density is maintained during bicalutamide ('Casodex') treatment. ASCO Annual Meeting 2002, May 18-21, Orlando, USA. Abstract 783
53. Smith MR Goode M Zietman AL McGovern FJ Lee H Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 2004 22: 2546 53
54. Wirth MP See WA McLeod DG Iversen P Morris T Carroll K Casodex Early Prostate Cancer Trialists' Group. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004 172: 1865 70
55. See WA Wirth MP McLeod DG et al. Casodex Early Prostate Cancer Trialist Group. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 2002 168: 429 35
56. Dicker AP. The safety and tolerability of low-dose irradiation for the management of gynaecomastia caused by antiandrogen monotherapy. Lancet Oncol 2003 4: 30 6
57. Boccardo F Rubagotti A Battaglia M et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005 23: 808 15
58. Rashid MH Chaudhary UB. Intermittent androgen deprivation therapy for prostate cancer. Oncologist 2004 9: 295 301
59. Bruchovsky N Rennie PS Coldman AJ Goldenberg SL To M Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990 50: 2275 82
60. Bruchovsky N Goldenberg SL Rennie PS Gleave M. [Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma]. Urologe A 1995 34: 389 92
61. Akakura K Bruchovsky N Goldenberg SL Rennie PS Buckley AR Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 1993 71: 2782 90
62. Sato N Gleave ME Bruchovsky N et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol 1996 58: 139 46
63. Goldenberg SL Gleave ME Bruchovsky N. Mechanisms of androgen-independent tumor growth. Can J Urol 1997 4 ( Suppl. 1 65 7
64. Pether M Goldenberg SL Bhagirath K Gleave M. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience. Can J Urol 2003 10: 1809 14
65. Hurtado-Coll A Goldenberg SL Gleave ME Klotz L. Intermittent androgen suppression in prostate cancer: the Canadian experience. Urology 2002 60 ( Suppl. 3 52 6
66. Kurek R Renneberg H Lubben G Kienle E Tunn UW. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 1999 35 ( Suppl. 1 27 31
67. Pether M Goldenberg SL. Intermittent androgen suppression. BJU Int 2004 93: 258 61
68. Gleave ME Goldenberg SL Jones EC Bruchovsky N Sullivan LD. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 1996 155: 213 9
69. Albrecht W Collette L Fava C et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study. Eur Urol 2003 44: 505 11
70. Calais da Silva F Bono A Whelan P et al. Intermittent androgen deprivation for locally advanced prostate cancer. Preliminary experience from an ongoing randomized controlled study of the South European urooncological group. Oncology 2003 65 ( Suppl. 1 24 8
71. Gleave ME Sato N Goldenberg SL Stothers L Bruchovsky N Sullivan LD. Neoadjuvant androgen withdrawal therapy decreases local recurrence rates following tumor excision in the Shionogi tumor model. J Urol 1997 157: 1727 30
72. Gulley JL Figg WD Steinberg SM et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol 2005 173: 1567 71
73. Tunn UW Kurek R Kienle E Maubach L. Intermittent is as effective as continuous androgen deprivation in patients with PSA-relapse after radical prostatectomy (RP). J Urol 2004 171 ( Suppl. 384
74. Higano C Shields A Wood N Brown J Tangen C. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. J Urol 2004 64: 1182 6
75. Lane TM Ansell W Farrugia D et al. Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urol Int 2004 73: 117 22
76. Malone S Perry G Segal R Dahrouge S Crool J. Long-term side effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study. BJU Int 2005 96: 514 20
77. de la Taille A Zerbib M Conquy S et al. Intermittent androgen suppression in patients with prostate cancer. BJU Int 2003 91: 18 22
78. Mottet N Lucas C Sene E Avances C Maubach L Wolff JM. Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer? Urol Int 2005 75: 204 8
79. Higano CS Ellis W Russell K Lange PH. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 1996 48: 800 4
80. Crook JM Szumacher E Malone S Huan S Segal R. Intermittent androgen suppression in the management of prostate cancer. Urology 1999 53: 530 4
81. Grossfeld GD Chaudhary UB Reese DM Carroll PR Small EJ. Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology 2001 58: 240 5
82. Sato N Akakura K Isaka S et al. Chiba Prostate Study Group. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Urology 2004 64: 341 5
83. Prapotnich D Fizazi K Escudier B Mombet A Cathala N Vallancien G. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 2003 43: 233 40
84. Peyromaure M Delongchamps NB Debre B Zerbib M. Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience. Urology 2005 65: 724 9
85. Tunn UW Kurek R Kienle E Maubach L. Intermittent is as effective as continuous androgen deprivation in patients with PSA-relapse after radical prostatectomy (RP). J Urol 2004 17 ( Suppl. 384
86. Bouchot O Lenormand L Karam G et al. Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol 2000 38: 543 9
87. Cherrier MM Rose AL Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol 2003 170: 1808 11
88. Da Silva FC Gonçalves F Santos A et al. Phase III study intermittent monotherapy versus continuous combined androgen deprivation: an international cooperative study. Program and. Abstracts of the AUA: Annual Meeting May 21-26, 2005 San Antonio, Texas. Abstract 813